Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma CME Congresses . Aug 1st 2023- Dr. Samer Al Hadidi- Risk of Infections Associated with the use of Bispecific Antibodies in Multiple Myeloma July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial CME Congresses . July 25th 2023- Dr. Olalekan Oluwole- His Take on the Overall Survival Update from the Randomized ZUMA-7 Trial July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results CME Congresses . July 17th 2023- Dr. Jordan Gauthier- CD19 CAR T-Cell Therapy & Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results July 7th 2023- Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues CME Congresses . July 7th 2023- Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues May 9th 2023- Dr. Olalekan Oluwole – Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL CME Congresses . May 9th 2023- Dr. Olalekan Oluwole – Approval of Polatuzumab Vedotin Plus R-CHP in Previously Untreated DLBCL May 5th 2023- Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation CME Congresses . May 5th 2023- Dr. Bhagirathbhai Dholaria- Omisirge Allogeneic Cord Blood-Based Cell Therapy Approved to Reduce Risk of Infection Following Stem Cell Transplantation Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma CME Congresses . Dr. Paula Rodríguez Otero- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy CME Congresses . Prof. Christoph Stein Thoeringer- Role of the Gut Microbiome in CAR-T cell Therapy Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium CME Congresses . Dr. Doris Hansen- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium Prof. Florent Malard- The First microbiota therapy approved by the US FDA CME Congresses . Prof. Florent Malard- The First microbiota therapy approved by the US FDA Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Page21 Page22 Page23 Page24
